Evidence map›Paper›PMID 9794504›Full record

ArticlePharmaceutical research1998

The effect of high dose endotoxin on CYP3A2 expression in the rat.

A L Roe, G Warren, G Hou, G Howard, S I Shedlofsky, R A Blouin

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

A L RoeGraduate Center for Toxicology, University of Kentucky, Lexington, USA.
G Warren
G Hou
G Howard
S I Shedlofsky
R A Blouin
University of Kentucky · USThe Graduate Center, CUNY · US

Funding

ENVIRONMETAL CARCINOGENESIS AND MUTAGENESIST32ES007250 · NIEHS · UNIVERSITY OF CINCINNATI · PI MILLER, WILLIAM E · 1988 to 2024
$11.9M
TRAINING GRANT IN MOLECULAR MECHANISMS OF TOXICITY.T32ES007266 · NIEHS · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI, MELLON, ISABEL W · 1990 to 2020
$3.7M
MECHANISMS OF HEAD TRAUMA INDUCED LUNG INJURYP01NS031220 · NINDS · UNIVERSITY OF KENTUCKY · PI KINDY, MARK S · 1994 to 1998
–
NIEHS NIH HHS 5 T32ES07250-10NIEHS NIH HHS 5 T32ES07266NINDS NIH HHS P01 NS31220
6 · The paper itself

Abstract

purposeThe purpose of our research was two-fold: 1) to further characterize the downregulation of CYP3A2 mRNA, protein, and activity during an acute phase response (APR); 2) most importantly, to relate the time-dependent activation of nuclear proteins to putative DNA binding sequences within the CYP3A2 5'-flanking region, with the loss in CYP3A2 expression.

methodsRats were injected (2.0 mg/animal, i.p.) with LPS and sacrificed at 1, 2, 4, 6, 8, 24, 48, and 72 hours. Hepatic nuclear protein was isolated and analyzed for binding activity to AP-1, NFkappaB, and NF-IL6 consensus sequences. Hepatic CYP3A2 mRNA levels were determined by solution hybridization and CYP3A2 protein, CYP3A2 activity, and total P450 were measured in hepatic microsomes.

resultsComputer analysis of the 5'-flanking region of CYP3A2 revealed the presence of 5 NF-IL6 and 4 AP-1 putative DNA binding sites. The strongest increase in AP-1 binding activity occurred between 6 and 24 hr, and the alteration in binding complexes to an NF-IL6 oligonucleotide occurred between 4 and 24 hr. Maximum loss in CYP3A2 mRNA occurred at 8 hr post-LPS injection and remained lowered at the 24 hr timepoint. CYP3A2 protein was significantly decreased at 24, 48, and 72 hours post-LPS treatment with corresponding decreases in CYP3A2 activity and total P450.

conclusionsThe changes in NF-IL6 and AP-1 binding after LPS treatment, which appears to correlate with the changes in CYP3A2 mRNA, combined with the presence of putative NF-IL6 and AP-1 sites located in the CYP3A25'-flanking region, may indicate a potential role for NF-IL6 and AP-1 in CYP3A2 downregulation during an APR.

Indexed as

Acute-Phase ReactionAnimalsCCAAT-Enhancer-Binding ProteinsCytochrome P-450 Enzyme SystemDNA-Binding ProteinsDown-RegulationEnzyme-Linked Immunosorbent AssayLipopolysaccharidesMaleNF-kappa BNuclear ProteinsRatsRats, Sprague-DawleyRNA, MessengerSteroid HydroxylasesTranscription Factor AP-1CCAAT-Enhancer-Binding ProteinsCytochrome P-450 Enzyme SystemDNA-Binding ProteinsLipopolysaccharidesNF-kappa BNuclear ProteinsRNA, Messengersteroid hormone 6-beta-hydroxylaseSteroid HydroxylasesTranscription Factor AP-1

Identifiers

PMID9794504
OpenAlexW29232333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.